Roth Capital Maintains Buy On Curis Following First Patient Dosed In Phase I Study Of CUDC-907
Roth Capital analyst Joseph Pantginis maintained a Buy rating on Curis Inc. (NASDAQ:CRIS) with a price target of $10, as the company announced dosing of first patient in its recently initiated Phase I study of CUDC-907 in r/r solid tumors.
Pantginis noted, “We view this newly initiated study favorably, expanding ‘907’s potential profile from hematological malignancies into solid tumors. As a dual inhibitor of HDAC and PI3K, ‘907 has the potential to hit tumor cells at multiple key cellular pathways, thereby disabling redundant survival and immune evasive mechanisms the cancer cells have adapted.”
The analyst continued, “We believe that the ‘907 data to date indicate a potential for this dual inhibitor to act as single agent and in combination setting and we look forward to solid tumor data in 2015.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of -2.7% and a 45.0% success rate. Pantginis has a -18.4% average return when recommending CRIS, and is ranked #3168 out of 3420 analysts.